OR WAIT 15 SECS
Melanie Sena is community editor of Pharmaceutical Technology.
AstraZeneca will receive $76 million in damages from Apotex Corp., Apotex, and Torpharm.
AstraZeneca reported a ruling by the US District Court for the Southern District of New York that ordered Apotex Corp., Apotex, and Torpharm, to pay AstraZeneca approximately $76 million in damages. This ruling is a result of Apotex’s infringing sales of generic omeprazole between 2004 and 2007. This follows a previous ruling in 2007 that found two Prilosec (omeprazole) formulation patents valid and infringed by Apotex.